Your partner in care INFORMATION AT YOUR FINGERTIPS
Further, together
During this challenging time, we are committed to continuing to educate and support healthcare professionals. We recognise that many are dealing with increasing complexities of workflow and may be busy supporting efforts to contain and treat Covid-19.
As needs evolve, we will continue to work with healthcare providers to navigate this new landscape and ensure that we go Further, Together.
WHAT FURTHER, TOGETHER MEANS DURING THE COVID-19 PANDEMIC AND BEYOND
Learn more
Remote Patient Management For The Post-Covid-19 Era: Practical Experience from Greater Manchester - - F.Z. Ahmed (Manchester, GB) - (08:14)
Future of Continuous Monitoring in a Remote Environment - A. Patwala (Newcastle-under-Lyme, GB) - (15:40) - (15:40)
Controversies and Myths in CRT - K. Witte (Leeds, GB) - (19:04)
Management of Heart Failure Patients Using a Device Based Risk Assessment Algorithm - F. Ahmed (Manchester, GB) - (11:18)) - (11:18)
Remote Management of Device HF Patients Using Risk Assessment Algorithms - H. Burri (Geneva, CH) - (13:22)
Which Patient Outcomes are Most Meaningful In Heart Failure? - M. Cowie (London, GB) - (17:20)
Implementing Remote Device Therapies in the Modern Heart Failure Clinic - W. Mullens (Genk, BE) - (20:41)
TYRX™ Envelope Recommended by International Consensus1
The TYRX™ Absorbable Antibacterial Envelope was recently provided a “Green Heart” recommendation by the European Heart Rhythm Association International Consensus Document on CIED infection prevention. The recommendation is for the WRAP-IT study population and patients with other high-risk factors. The consensus document is endorsed by seven international societies.
learn more
MEDICATION ALONE IS NOT ENOUGH TO HELP ALL HF PATIENTS2
The HeartWare™ HVAD™ Pump is the smallest, full-support centrifugal VAD designed to be implanted completely within the pericardial space.
LEARN MORE
Reducing Unnecessary Shocks with Device Features and New Smart Technologies - A. Rao (Warrington, GB) - (12:49) - (12:49)
the Future IS HERE
Meet Cobalt XT ICDs and CRT-Ds
Exclusive ATP algorithm, heart failure risk stratification, tablet-based programming and app-based remote monitoring, extended longevity, and 40 J on all shocks.
Fewer Shocks. Greater Living.
Did you know that we are celebrating the 10-year anniversary of SmartShock? This smart technology can help steer patients clear of inappropriate and unnecessary shocks.3,4
LEARN MORE
His Bundle Pacing: Where Do We Stand? - Z. Whinett (London, GB) - (21:31) - (21:31)
LEADLESS PACING: THE FUTURE IS HERE
LEARN MORE
DIFFERENTIATED INNOVATION IN cardiac ablation
LEARN MORE
ONYX ONE MONTH
DAPT PROGRAM
Results showed Resolute Onyx™ DES was safe and effective in HBR patients with 1-month DAPT.6,7 Listen to steering committee members discuss the Onyx ONE Global study results.
Find out moreReferences
Blomström-Lundqvist C, Traykov V, Erba PA, et al. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Europace. Published online November 8, 2019.
Schlöglhofer T, Horvat J, Moscato F, et al. A Standardized Telephone Intervention Algorithm Improves the Survival of Ventricular Assist Device Outpatients. Artif Organs. 2018;42(10):961-969. doi:10.1111/aor.13155.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. Aug 2016;18(8):891-975.
Auricchio A, Schloss EJ, Kurita T, Meijer A, Gerritse B, Zweibel S, Al Smadi FM, Leng CT, Sterns LD, on behalf of the PainFree SST Investigators. Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results. Heart Rhythm 2015;12:926-936.
Regoli F, Graf D, Schaer B, Duru F, Ammann P, Mangoni di S. Stefano6 L, Naegli B, Burri H, Zbinden R, Krasniqi N, Fromer M and 4P Study Group. Arrhythmic episodes in patients implanted with a cardioverter-defibrillator – results from the Prospective Study on Predictive Quality with Preferencing PainFree ATP therapies (4P). BMC Cardiovascular Disorders (2019) 19:146
Kirtane A, et al. One Month Dual Antiplatelet Therapy in High Bleeding Risk Patients: Primary Results of Onyx ONE Clear. Presented online at ACC 2020.
Windecker S, Latib A, Kedhi E, et al. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. N Engl J Med. March 26, 2020;382(13):1208-1218.
See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. If using an MRI Sure ScanTM device, see the MRI SureScanTM technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic webisite at medtronic.eu.
For applicable products, consult instructions for use on medtronic.com/manuals. Manuals can be viewed using a current verision of any major internet browser. For best results use Adobe Acrobat Reader® with the browser.
The data and content included in these presentations express only the clinical perspective of the presenter. They are completely independent and do not necessarily reflect the opinions of Medtronic.